Enlarged Board of Appeal fails to offer clear guidance in highly-anticipated “plausibility” opinion
The EBA has not laid out clear rules about when post-filed evidence can be used to demonstrate technical effect
The EBA has not laid out clear rules about when post-filed evidence can be used to demonstrate technical effect
The High Court of England and Wales has shifted the momentum of the spat, with the EPO Technical Board of Appeal set to hear a related case tomorrow
In the life sciences industry, patent protection for innovative medicinal products is pivotal to the commercial success of new drug products.
29 September 2022
Turkey’s recent compulsory licence decision shines a light on the questionable use of compulsory licence provisions around the world in relation to the pandemic. The creation of the covid vaccine has sparked discussions on IP rights and where the real regulatory focus should be.
28 September 2022
Dr Kenneth Wong, of Singapore-based MiRXES, discusses using a multi-faceted IP approach to propel the company forward
22 September 2022
Exclusive IAM interview with the university’s tech transfer chief Vjera Magdalenic-Moussavi
19 September 2022
Titan Medical IP chief discusses need for standards in innovative healthcare
15 September 2022
US university litigation seeks damages and ongoing royalties over blockbuster heart failure drug which generated $2.22 billion in 2H 2022
13 September 2022
The top court speedily backed an earlier judgment against rights owner Chugai Pharmaceuticals
08 September 2022
Martin Zorrilla, CTO of Singapore-based insect farming start-up Nutrition Technologies, explains how capturing, protecting and exploiting the company’s know-how creates new opportunities, as well as peace of mind
08 September 2022
Patent-backed rare disease innovations secure more M&A/licensing investment than any pharma assets outside oncology
07 September 2022
New IAM and Docket Navigator litigation report reveals key trends, including declining semiconductor asset challenges
06 September 2022
Unlock unlimited access to all IAM content